

PATENT

Case Docket No. NEREUS.2C1CP1

Date: January 30, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hayashi, et al.
Appl. No. : 10/632,688
Filed : August 1, 2003
For : PHENYLAHISTIN AND THE
PHENYLAHISTIN ANALOGS,
A NEW CLASS OF ANTI-
TUMOR COMPOUNDS
Examiner : Unknown
Group Art Unit : 1614

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 30, 2004

(Date)

Marc T. Morley, Reg. No. 52,051

TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 listing 10 references, which are not enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Marc T. Morley
Registration No. 52,051
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant	:	Hayashi, et al.
App. No.	:	10/632,688
Filed	:	August 1, 2003
For	:	PHENYLAHISTIN AND THE PHENYLAHISTIN ANALOGS, A NEW CLASS OF ANTI-TUMOR COMPOUNDS
Examiner	:	Unknown
Group Art Unit	:	1614

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing ten (10) references that are of record in U.S. patent application No. 09/995,851, filed November 27, 2001, which is the parent of this continuation-in-part application; which application is a continuation of U.S. patent application No. 09/440,316, filed November 12, 1999, and is relied upon for an earlier filing date under 35 U.S.C. § 120. Copies of the ten references are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 1/30/04

By: M. T. Morley

Marc T. Morley
Registration No. 52,051
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NEREUS.2C1CP1	APPLICATION NO. 10/632,688
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hayashi, et al.	
		FILING DATE August 1, 2003	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	6,069,146	5/2000	Fenical, et al.			
	2	6,358,957	3/2002	Fukumoto, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	3	2,143,823	2/1985	Great Britain				
	4	5009164	1/1993	Japan				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	5	Dandan, et al., JP 5009164-CA 119: 8514 (1993).
	6	Kim, et al., "Polymer attached cyclic peptides, <i>Tetrahedron: Asymmetry</i> ," 3(11) 1421-30 (1992).
	7	Kanoh, et al., "Phenylahistin: A new mammalian cell cycle inhibitor produced by <i>asperigillus ustus</i> ", <i>Bio. & Med. Chem. Lett.</i> , Vol. 7, pp. 2847-2852 (1997).
	8	Kanoh, et al., "Synthesis and Biological Activities of Phenylahistin Derivatives", <i>Bio. & Med. Chem.</i> , 1-7 (1999).
	9	Kanoh, et al., "Antitumor Activity of Phenylahistin in Vitro and in Vivo", <i>Biochem, Biosc. Biotec.</i> , 63 (6), 1130-1133 (1999).
	10	Kanoh, et al., "(-)-Phenylahistin Arrests Cells in Mitosis by Inhibiting Tubulin Polymerization", <i>The Journal of Antibiotics</i> , V. 52, No. 2, (Feb. 1999).

S:\DOCS\WMTMMTM-5147 -DOC:dmr
013004

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	